Rapid responses are electronic comments to the editor. They enable our users
to debate issues raised in articles published on bmj.com. A rapid response
is first posted online. If you need the URL (web address) of an individual
response, simply click on the response headline and copy the URL from the
browser window. A proportion of responses will, after editing, be published
online and in the print journal as letters, which are indexed in PubMed.
Rapid responses are not indexed in PubMed and they are not journal articles.
The BMJ reserves the right to remove responses which are being
wilfully misrepresented as published articles or when it is brought to our
attention that a response spreads misinformation.
From March 2022, the word limit for rapid responses will be 600 words not
including references and author details. We will no longer post responses
that exceed this limit.
The word limit for letters selected from posted responses remains 300 words.
Let me be among the first to offer support for more Pragmatic Clinical Trials as a functional way to improve health care delivery and economics in the US and abroad. As more Exploratory Trials head to the East to offer Sponsors and CROs economies of scale, those of us in the West may be wise to ponder the applicability of such work with indigenous populations. To wit, US Obesity rates are climbing above 30% in several US States, so what efficacy can be expected in populations where Metabolic Syndromes are at epidemic levels? There are manifold benefits to leveraging Electronic Health Records in Real World/Pragmatic clinical settings that are compelling.
Re: Understanding controlled trials: What are pragmatic trials?
Let me be among the first to offer support for more Pragmatic Clinical Trials as a functional way to improve health care delivery and economics in the US and abroad. As more Exploratory Trials head to the East to offer Sponsors and CROs economies of scale, those of us in the West may be wise to ponder the applicability of such work with indigenous populations. To wit, US Obesity rates are climbing above 30% in several US States, so what efficacy can be expected in populations where Metabolic Syndromes are at epidemic levels? There are manifold benefits to leveraging Electronic Health Records in Real World/Pragmatic clinical settings that are compelling.
Competing interests: No competing interests